Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries.
What Glenmark files
- Updates77
- Others38
- Investor Meet32
- Important18
- Dividend/Bonus8
- PPTs7
Glenmark Pharmaceuticals Limited has informed the Exchange about Investor Presentation
Glenmark Pharma delivered a strong Q4 FY26, with consolidated revenue rising 15.8% YoY to Rs. 3,770.6 Cr. Profit after tax (PAT) stood at Rs. 301.3 Cr, and EBITDA reached Rs. 762.6 Cr (20.2% margin). Regional growth was robust, with Europe up 21.4%, North America growing 29.4% (boosted by out-licensing income),...
Glenmark Pharma Q3 FY26 consolidated revenue rose 15.1% YoY to ₹3,900.6 Cr. India led with 22.1% growth, North America's core business grew 4.1% (excluding out-licensing income), Europe gained 9.1%, and Emerging Markets 8.4%. EBITDA hit ₹869.7 Cr with a 22.3% margin. PAT was ₹403.2 Cr, including an exceptional item of...
Here's a summary of Glenmark Pharmaceuticals Limited's Q1 FY26 performance: **1. Financial Highlights:** Consolidated revenue hit ₹3,264.4 Cr (+0.6% YoY) for Q1 FY26. EBITDA reached ₹580.5 Cr (17.8% margin), with adjusted PAT at ₹312.9 Cr (9.6% margin). India business grew 3.7% to ₹1,239.9 Cr, while North America saw an 8.9%...
1. Financial Highlights: Consolidated revenue for Q4 reached Rs 3,256.2 Cr, up 6.3% YoY, with strong growth in Europe (+19.9%) and Rest of World (+4.9%) offsetting a 5.4% decline in North America. FY25 revenue rose 12.8% to Rs 13,321.7 Cr, driven by India (+31.9%) and Europe (+17.6%). EBITDA margin held...